Information Provided By:
Fly News Breaks for September 14, 2017
ALXN
Sep 14, 2017 | 07:59 EDT
Leerink analyst Geoffrey Porges notes that Alexion announced the presentation of additional results from the open-label extension of the pivotal phase III REGAIN study of Soliris in refractory generalized myasthenia gravis. The analyst believes this longer-term follow-up analysis is highly supportive of the upcoming PDUFA on October 23. Porges reiterates an Outperform rating and $182 price target on the shares.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.